List view / Grid view

Eli Lilly & Company

New data for Trulicity and Tradjenta in type 2 diabetes

13 June 2016 | By European Pharmaceutical Review

Lilly has announced new findings from separate studies of Trulicity (dulaglutide) and Tradjenta (linagliptin) at the American Diabetes Association 76th Scientific Sessions.

news

New data for baricitinib in rheumatoid arthritis presented at EULAR

9 June 2016 | By Victoria White (European Pharmaceutical Review)

Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).

news

Data for Alimta and Cyramza plus keytruda in NSCLC presented at ASCO

6 June 2016 | By Victoria White, Digital Content Producer

Data were presented from two early-phase trials evaluating Lilly's Alimta and Cyramza in combination with Merck's Keytruda in patients with NSCLC...

news

Lilly’s psoriasis drug Taltz to generate sales over $1 billion by 2022

11 May 2016 | By Victoria White, Digital Content Producer

Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.

news

FDA grants Priority Review for olaratumab BLA

4 May 2016 | By Victoria White, Digital Content Producer

The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.

news

Positive topline results from a Phase Ib study of BioChaperone Lispro

28 April 2016 | By Victoria White, Digital Content Producer

Adocia and Lilly have announced positive topline results from a Phase Ib trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro...

news

EC grants marketing authorisation to Lilly’s ixekizumab

26 April 2016 | By Victoria White, Digital Content Producer

The EC has granted marketing authorisation for Lilly’s ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults...

news

Jardiance to be investigated in chronic heart failure trials

19 April 2016 | By Victoria White, Digital Content Producer

Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure...

news

Adocia initiates Phase Ib study of HinsBet in type 1 diabetes

12 April 2016 | By Victoria White, Digital Content Producer

HinsBet is a rapid-acting formulation of recombinant human insulin using BioChaperone, which is designed to accelerate insulin absorption...

news

Phase II/III trial of AZD3293 in early Alzheimer’s disease to continue

8 April 2016 | By Victoria White

AstraZeneca and Lilly have announced that AMARANTH, a Phase II/III study of AZD3293 will continue into Phase III of the Phase II/III seamless trial...

news

Lilly and Incyte announce results from RA-BEACON baricitinib study

31 March 2016 | By Victoria White (European Pharmaceutical Review)

Lilly and Incyte have announced results from the RA-BEACON Phase III study of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis (RA).

news

FDA approves Lilly’s Taltz for plaque psoriasis

23 March 2016 | By Victoria White

Taltz (ixekizumab) is intended for adult patients who are candidates for systemic therapy, phototherapy or a combination of both...

news

Lilly changes the primary endpoint of the EXPEDITION3 Alzheimer’s trial

15 March 2016 | By Victoria White

Lilly has made a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer's dementia...

news

Lilly presents new data from the UNCOVER-2 trial of ixekizumab

8 March 2016 | By Victoria White

In UNCOVER-2, patients with plaque psoriasis who did not respond to etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab...

news

CHMP adopts positive opinion for Lilly’s ixekizumab

26 February 2016 | By Victoria White

Ixekizumab is an IgG4 monoclonal antibody that selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor...

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Eli Lilly & Company